FDA Committee Backs Netarsudil, a Once-Daily Glaucoma Drug

The FDA advisory committee approved a new drug application for once-daily glaucoma drug netarsudil (Rhopressa), introducing a new drug class for this indication.
Medscape Medical News

Full Story →